Pharmaceutical

Bradmer Completes Previously Announced Private Placement

WuXi PharmaTech Inc. announced today that its previously announced transaction with Charles River Laboratories International Inc. has been terminated by mutual agreement due to Charles River shareholder opposition. Under the terms of the ...

Charles River Laboratories International, Inc. , a leading global provider of research models and associated services and of preclinical drug development services, today announced that it has mutually agreed with WuXi PharmaTech Inc. to terminate ...

Medistem Inc. announced today publication of a peer reviewed paper identifying a molecule found on the company's lead product, the universal donor Endometrial Regenerative Cell , as a key component of cellular escape from immune attack. The study, ...

Orexigen® Therapeutics, Inc. announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, ...

Depomed, Inc. announced today that it will release second quarter 2010 financial results after the market closes Thursday, August 5, 2010. The company will host a conference call beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results.

Actient Pharmaceuticals, LLC , a portfolio company of GTCR, announced today the company successfully completed a transaction to license and acquire six pharmaceutical products from UCB, Inc., a subsidiary of UCB SA , an international ...

GTCR, one of the country's leading private equity firms, announced today that Actient Pharmaceuticals, LLC has successfully completed a transaction to license and acquire six pharmaceutical products from UCB, Inc., a subsidiary of UCB SA, an ...